AI for Core IT

Robotic Process Automation Enhanced with AI in Pharma Back-Office

ANG Associates
Life Sciences & AI Consulting

Dec 2025 5 min read

The Back-Office Bottleneck in Pharma Operations

Pharmaceutical and life sciences companies run some of the most document-heavy back offices in any industry. Invoices from thousands of vendors, deviation reports from manufacturing floors, batch records that must be reviewed line by line, and procurement approvals all move through processes that are highly structured on paper but riddled with exceptions in practice. A purchase order does not match a delivery note. A batch record contains a handwritten annotation. A deviation report describes a scenario nobody wrote a rule for. Traditional, rules-based Robotic Process Automation (RPA) handles the predictable 80 percent of these workflows well, but it stalls the moment a document or a decision falls outside its scripted path, routing the exception back to a person and eroding much of the efficiency gain.

This is precisely the gap that artificial intelligence is now closing. By pairing RPA bots with machine learning models, most commonly for document understanding, natural language processing, and pattern-based anomaly detection, pharma organizations are extending automation from simple, structured tasks into the judgment-heavy exception queue that used to require a human every time.

How AI-Enhanced RPA Handles Exceptions

In an AI-enhanced automation setup, the RPA bot still performs the deterministic steps: logging into systems, moving data between platforms, and executing approved transactions. What changes is what happens when a case does not fit the standard pattern. Instead of failing over to a manual queue by default, an ML layer classifies the exception, extracts the relevant data even from messy or semi-structured documents, and either resolves it automatically within a confidence threshold or routes it to a person with the relevant context already assembled.

Invoice processing: Document understanding models read semi-structured and unstructured invoices, extract line-item data, and flag mismatches for accounts payable teams, with the model's accuracy improving over time as it is corrected and retrained on new invoice variations.
Deviation and quality event management: Natural language processing tools scan deviation narratives and batch documentation to detect anomalies and classify severity, escalating only the cases that genuinely need a quality professional's judgment.
Batch record review: According to the trade association ISPE, bots can autonomously close out electronic batch record reviews when no anomalies are present and escalate only genuine inconsistencies for human evaluation, shifting reviewers from checking every record to investigating true exceptions.
Procurement and vendor management: Automation Anywhere describes bots handling supplier onboarding, vendor data collection from PDFs and emails, and compliance verification, tasks that combine rules-based steps with AI-driven document interpretation.

ISPE's analysis of RPA in the pharmaceutical industry also makes the compliance case directly: RPA systems are well suited to validated environments because they are "configurable, auditable, and specifically designed to not 'color outside the lines,'" with built-in adherence to standard operating procedures and comprehensive audit trails, exactly the properties a GxP-validated process demands.

What the Evidence Shows

Real deployments illustrate both the opportunity and the discipline required to capture it. Thermo Fisher Scientific's Global Business Services team combined UiPath Document Understanding, AI Center, and Action Center to process highly variable vendor invoices at scale. The published case study reports a 70 percent reduction in invoice processing time across roughly 824,000 invoices processed annually, with 53 percent of invoices moving through straight-through processing with no human touch at all, while the remainder were routed to human reviewers through Action Center for validation.

"The more we use it, the better it gets," said Luis Cajiao, Senior Manager of Smart Automation at Thermo Fisher Scientific, describing how the model's accuracy improved through continuous use and feedback.

Broader industry research supports this direction. McKinsey's analysis of automation in the US biopharma industry found that machine learning and RPA could affect a large share of manufacturing and administrative work, including record-to-report finance processes, with roughly 30 percent of the biopharma manufacturing workforce seeing some task automation by 2030. Automation Anywhere, citing McKinsey research separately, notes that up to half of existing work in pharmaceutical and medical manufacturing could be automated over a decade, alongside rising demand for judgment-based skills as routine work moves to bots. Deloitte's work on AI in pharma highlights a parallel dynamic in pharmacovigilance, where adverse event report volume is growing 10 to 15 percent annually, making OCR- and NLP-driven case intake automation a practical necessity. ISPE's commentary on AI in quality operations frames this as a shift from "reactive correction to predictive and preventive control," where intelligent batch record review and automated deviation detection let quality teams focus on events that genuinely require judgment.

None of these sources describe a frictionless rollout. The consistent theme across the UiPath case study, ISPE's technical guidance, and the analyst commentary is that AI-enhanced RPA works when exception handling is designed deliberately, with clear confidence thresholds, human review points, and retraining loops, not when it is treated as a set-and-forget layer on top of existing bots.

Where ANG Associates Fits

Delivering AI-enhanced RPA in a GxP environment is a different exercise than deploying automation in a typical back office. Every model that touches batch records, deviations, or quality data needs to sit inside a validated, auditable process, with documented decision logic, defined escalation paths, and evidence that the system behaves consistently across releases. ANG Associates works at exactly this intersection: AI strategy paired with GxP computer system validation, so that an intelligent automation program is not just built to work, but built to pass an audit.

ANG's SAFe and Agile delivery practice brings the same discipline to how these programs are run. Intelligent automation initiatives touch finance, quality, procurement, and IT simultaneously, and they tend to fail when treated as a single monolithic rollout rather than an iterative program with clear increments, validation checkpoints, and measurable exception-rate improvements at each stage. ANG's IT delivery management experience in pharma and life sciences means these programs are scoped, sequenced, and governed with the regulatory and operational realities of the industry built in from day one, rather than retrofitted after a pilot stalls in the validation queue.

Sources

intelligent automationRPApharma back-officeGxP compliancequality operations

Interested in this topic?

Let's discuss how we can apply these approaches to your organization.